8-K: Shuttle Pharmaceuticals Enters Research Agreement with UCSF to Advance Prostate Cancer Theranostic

Shuttle Pharmaceuticals has partnered with the University of California, San Francisco to further develop a prostate-specific membrane antigen (PSMA) ligand for potential diagnostic and therapeutic applications.

Summary

• Shuttle Pharmaceuticals has entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance the development of a PSMA ligand.
• The research will focus on a molecule called PSMA-B, which has shown nanomolar binding activity to PSMA and contains boron.
• The agreement includes a $291,607 research program to be conducted by UCSF, with Shuttle Pharma holding an exclusive license to the underlying intellectual property.
• The research aims to develop methods for radiolabeling the PSMA ligand with fluorine-18, investigate its binding properties in prostate cancer cell lines, and evaluate its diagnostic potential in mouse models.
• Shuttle Pharma has an exclusive license to the intellectual property and has filed a patent application.
• The global PSMA PET imaging market is estimated to reach $2 billion by 2030, with Pluvicto, a targeted radiopharmaceutical, having a predicted market size of $2 billion.

Sentiment

Score: 7

Explanation: The document is positive due to the research agreement with a reputable institution and the potential of the PSMA ligand. However, it is still early-stage research, so there is some uncertainty.

Positives

• The agreement with UCSF provides access to expert researchers and facilities for the development of the PSMA ligand.
• The PSMA-B ligand has shown promising nanomolar binding activity to PSMA, a key target in prostate cancer.
• The use of fluorine-18 for radiolabeling offers advantages in PET imaging due to its high resolution and longer half-life.
• The exclusive license and patent application provide a competitive advantage for Shuttle Pharma.
• The large and growing market for PSMA-targeted diagnostics and therapeutics presents a significant commercial opportunity.

Risks

• The research program is in the early preclinical stage, and there is no guarantee of success.
• The development of a successful theranostic agent is complex and may face challenges.
• The market for PSMA-targeted therapies is competitive, with other companies also developing similar products.
• The research agreement is for one year and may not be extended.

Future Outlook

The company aims to develop a theranostic agent for prostate cancer that can be used for both diagnosis and therapy. The research agreement with UCSF is a step towards achieving this goal. The company is also exploring the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy.

Management Comments

• Anatoly Dritschilo, M.D., Chairman and CEO of Shuttle Pharma, stated that PSMA is a valuable target for diagnosis and therapy of prostate cancer.
• Dr. Dritschilo also mentioned that the agreement with UCSF will support further preclinical testing in a mouse model of prostate cancer.
• Dr. Dritschilo expressed excitement about working with Dr. Flavell and his team at UCSF to advance the development of their PSMA-B ligand.

Industry Context

The announcement is relevant to the broader trend of developing targeted therapies and diagnostics for cancer, particularly in the field of radiopharmaceuticals. The PSMA target is well-established in prostate cancer, and the development of new ligands and radiolabeling methods is an active area of research. The market for PSMA-targeted agents is growing rapidly, driven by the need for more effective and personalized treatments.

Comparison to Industry Standards

• The development of PSMA-targeted theranostics is a competitive field, with companies like Novartis (Pluvicto) and Telix Pharmaceuticals (Illuccix) already having products on the market.
• The use of fluorine-18 as a radiolabel is a common approach in PET imaging, with examples like 18F-FDG being widely used.
• The research program at UCSF is focused on developing a novel method for radiolabeling ACUPA, a PSMA ligand, which could provide a competitive advantage.
• The market size estimates for PSMA PET imaging and Pluvicto are consistent with industry reports and projections.
• The preclinical research program is similar to other early-stage development programs in the radiopharmaceutical space, with a focus on in vitro and in vivo testing.

Stakeholder Impact

• Shareholders may view this agreement positively as it represents progress in the company's research and development efforts.
• Employees may be motivated by the potential of the research to improve cancer treatment outcomes.
• Patients with prostate cancer may benefit from the development of new diagnostic and therapeutic options.
• The agreement may strengthen the company's relationships with research institutions and potential partners.

Next Steps

• UCSF researchers will conduct the research program, including developing radiosynthetic methods for producing the [18F]FPA-ACUPA probe.
• The cellular binding properties of the probe will be investigated in prostate cancer cell lines.
• The diagnostic potential of the probe will be evaluated in mouse models of prostate cancer.
• Shuttle Pharma will decide within 60 days of disclosure if they wish to secure a commercial license for any inventions.
• Shuttle Pharma will have 90 days from the date of election to conclude a license or option agreement with UCSF.

Key Dates

Keywords

PSMA, prostate cancer, theranostic, radiolabeling, fluorine-18, PET imaging, Shuttle Pharmaceuticals, UCSF, ligand, PSMA-B